Last reviewed · How we verify

Caprelsa — Competitive Intelligence Brief

Caprelsa (VANDETANIB) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Kinase Inhibitor [EPC]. Area: Oncology.

marketed Kinase Inhibitor [EPC] Receptor-interacting serine/threonine-protein kinase 2 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Caprelsa (VANDETANIB) — Sanofi. Caprelsa works by blocking a specific protein that helps cancer cells grow and spread.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Caprelsa TARGET VANDETANIB Sanofi marketed Kinase Inhibitor [EPC] Receptor-interacting serine/threonine-protein kinase 2 2011-01-01
Vizimpro Dacomitinib Pfizer Inc. marketed Tyrosine kinase inhibitor (TKI); Pan-HER inhibitor Cyclin-G-associated kinase, Receptor-interacting serine/threonine-protein kinase 2, Receptor-interacting serine/threonine-protein kinase 3
Itovebi INAVOLISIB Genentech Inc marketed Kinase Inhibitor [EPC] 2025-01-01
Hernexeos ZONGERTINIB Boehringer Ingelheim marketed Kinase Inhibitor [EPC] 2025-01-01
Romvimza VIMSELTINIB Deciphera Pharms marketed Kinase Inhibitor [EPC] 2025-01-01
Wayrilz RILZABRUTINIB Genzyme Corp marketed Kinase Inhibitor [EPC] 2025-01-01
Ojemda TOVORAFENIB Day One Biopharms marketed Kinase Inhibitor [EPC] 2024-01-01

Recent regulatory actions (last 90 days)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Kinase Inhibitor [EPC] class)

  1. · 12 drugs in this class
  2. Pfizer · 7 drugs in this class
  3. Novartis · 3 drugs in this class
  4. Bayer · 2 drugs in this class
  5. Boehringer Ingelheim · 2 drugs in this class
  6. AstraZeneca · 2 drugs in this class
  7. Beigene Usa Inc · 1 drug in this class
  8. BeiGene · 1 drug in this class
  9. AbbVie · 1 drug in this class
  10. Bristol · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Caprelsa — Competitive Intelligence Brief. https://druglandscape.com/ci/vandetanib. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: